1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
HEAL Initiative: Preventing Opioid Use Disorder (OUD) is sponsored by National Institute on Drug Abuse (NIDA). HEAL Initiative: Preventing Opioid Use Disorder (OUD) is a federal funding program from the National Institute on Drug Abuse (NIDA) that supports research to prevent opioid addiction, discover new pain treatments, and develop non-opioid analgesics.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
A **. gov** website belongs to an official government organization in the United States.
* MedlinePlus Health Info * Science Education Resources * NIH Clinical Research Trials and You * Your Healthiest Self: Wellness Toolkits * Talking With Your Doctor or Health Care Provider * Medical Research Initiatives * Research in NIH Labs & Clinics * Clinical Research Resources * Safety, Regulation & Guidance * Lasker Clinical Research Scholars * List of Institutes and Centers * NIH Office of the Director * Directors of NIH Institutes and Centers * NIH...
Turning Discovery Into Health® * Science, Health, and Public Trust ## The Helping to End Addiction Long-term® Initiative The NIH HEAL Initiative® is an NIH-wide effort to improve prevention and treatment strategies for opioid misuse and addiction and to enhance pain management.
Established in April 2018, the NIH HEAL Initiative® (Helping to End Addiction Long-term®) is a congressionally funded program created to accelerate scientific solutions to America’s opioid crisis. Multiple institutes and centers within NIH collaborate under HEAL, advancing research across many fronts to meet this urgent public health emergency.
This page last reviewed on March 20, 2026 National Institutes of Health NIH…Turning Discovery Into Health® * Freedom of Information Act * Nondiscrimination Notice Looking for U.S. government information and services? [](https://heal. nih.
gov/funding/awarded? combine=&goal=All&grant=All&institutions=&institutions1=&items_per_page=25&locations=&locations1=&research_program=116&rfa=All&select_location=All&year=&page=1&order=field_institutions&sort=asc#)
According to the current listing, eligibility includes: Non-profit organizations, including institutions of higher education and community clinics. Confirm the full requirements in the official notice before applying.
HEAL Initiative: Preventing Opioid Use Disorder (OUD) is funded by National Institute on Drug Abuse (NIDA). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleARPA-H's FASTPASS program targets a public-health blind spot: substandard and contaminated drugs that are only caught after patients are exposed. It funds through-package chemical sensing (TA1 SAMPLE) and the analytics to act on it (TA2 DETECT). The solicitation posts to SAM.gov in mid-August 2026, with a virtual Proposer Workshop on August 24 and registration closing August 20. Here is what FASTPASS funds, why the timing matters, and how to position a cross-disciplinary team.
Read articleARPA-H PROSPR program funds seven research teams testing rapamycin, semaglutide, and novel compounds to extend healthspan. A deep analysis of the science, the money, and what it means for the field.
Read article